AreImmunogen (NASDAQ:IMGN) Shares Worth Your Dime? Piper Jaffray Believes So

September 8, 2018 - By Matthew Richard

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Investors sentiment decreased to 0.95 in 2018 Q1. Its down 0.43, from 1.38 in 2017Q4. It worsened, as 24 investors sold ImmunoGen, Inc. shares while 59 reduced holdings. 35 funds opened positions while 44 raised stakes. 102.59 million shares or 1.04% more from 101.53 million shares in 2017Q4 were reported.

Moreover, Quantitative Systematic Strategies Ltd Liability Com has 0.03% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Drw Secs Ltd Company has 0.01% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Creative Planning invested in 12,592 shares. Massachusetts-based Panagora Asset Incorporated has invested 0.04% in ImmunoGen, Inc. (NASDAQ:IMGN). Schwab Charles Inv Inc reported 531,076 shares. D E Shaw And Company Inc stated it has 114,433 shares or 0% of all its holdings. Ghost Tree Ltd Liability holds 0.05% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 7,500 shares. Quantbot Technologies Ltd Partnership stated it has 8,264 shares. Moreover, Primecap Mngmt Ca has 0.03% invested in ImmunoGen, Inc. (NASDAQ:IMGN). State Street Corporation holds 0.01% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 7.24 million shares. Gould Asset Mgmt Ltd Llc Ca owns 15,000 shares or 0.07% of their US portfolio. Parametric Portfolio Assoc Ltd Company holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 162,728 shares. Hall Laurie J Trustee invested in 0% or 380 shares. Bnp Paribas Arbitrage accumulated 0% or 20,606 shares. Bb&T Securities Llc holds 76,661 shares.

Since March 15, 2018, it had 0 insider buys, and 3 sales for $525,905 activity. JUNIUS DANIEL M also sold $300,405 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Friday, March 16.

How Piper Jaffray Currently Rates Immunogen (NASDAQ:IMGN)

Piper Jaffray has begun its coverage on Immunogen (NASDAQ:IMGN), today 7 September. The firm finds the stock of Immunogen (NASDAQ:IMGN) attractive and has given it “Overweight” rating.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Among 4 analysts covering ImmunoGen (NASDAQ:IMGN), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. ImmunoGen has $2000 highest and $500 lowest target. $13.33’s average target is 42.57% above currents $9.35 stock price. ImmunoGen had 4 analyst reports since March 26, 2018 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Monday, March 26. Canaccord Genuity maintained the shares of IMGN in report on Monday, March 26 with “Buy” rating. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Buy” rating by Leerink Swann on Friday, April 27. Cantor Fitzgerald maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Friday, April 6 with “Hold” rating.

The stock increased 0.32% or $0.03 during the last trading session, reaching $9.35. About 1.52M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 105.72% since September 8, 2017 and is uptrending. It has outperformed by 93.15% the S&P500.

Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on November, 2. They expect $-0.30 EPS, up 18.92 % or $0.07 from last year’s $-0.37 per share. After $-0.30 actual EPS reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.39 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Another recent and important ImmunoGen, Inc. (NASDAQ:IMGN) news was published by which published an article titled: “Premarket analyst action – healthcare” on September 07, 2018.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.